NUDT1 and pancreatic neoplasm: Consistent with our results, meta-analyses of public datasets indicate that RAS-driven tumors, such as pancreatic cancer or lung adenocarcinoma, show poor disease prognosis and higher relapse rates in tumors where MTH1 is elevated (Figure 1).